Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Breast Neoplasms: HELP
Alejandra Bruna
Based on 16 articles published since 2009
(Why 16 articles?)
||||
Expertise Level
The expertise of Alejandra Bruna ranks in the
  • Top 0.97%
  • ... of 265,285 published authors worldwide on Breast Neoplasms
  • ... from 2009 through 2019
  • ... based on contributions to 16 articles on the topic.
Graphical view (beta)
Get your prestigious
Expert badge
similar to this:
 
Aliases Bruna, Alejandra   ·   Bruna, A
Work Locations
Details
Most likely:    University of Cambridge      
2019
  • Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada. · NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK. · Strangeways Research Laboratory, University of Cambridge, Cambridge, UK. · Departamento de Estadística e Investigación Operativa, Universidad de Valladolid, Valladolid, Spain. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Pubmed 30867590
2018
  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada. · Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada. · CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada. · Department of Medical Oncology, University Hospital of Parma, Parma, Italy. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain. · CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. · Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Pathology, Dalhousie University, Halifax, NS, Canada. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · AstraZeneca, Waltham, MA, USA. · Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · XenTech, Evry, France. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Pubmed 30377213
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Regenerative Medicine Center, University Medical Center Utrecht Uppsalalaan 6, Utrecht, The Netherlands. · Mechanisms of Transcription Laboratory, The Francis Crick Institute, London NW1 1AT, UK. · Cancer Research UK Cambridge Institute, and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3484 EA Utrecht, The Netherlands. · Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge CB2 2QQ, UK. · Pubmed 30137431
  • The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Academic Urology Group, Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Institute of Molecular Biology (IMB), Mainz, Germany. · Department of Biochemistry, University of Cambridge, Cambridge, UK. · Wellcome Trust Sanger Institute, Hinxton, UK. · AstraZeneca, Waltham, MA, USA. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · AstraZeneca, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Pubmed 30022119
  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, UK. · Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Pubmed 29795445
  • Department of Oncology, University of Torino Medical School, Torino, Italy. · Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. · Molecular Medicine Program, European Institute of Oncology, Milan, Italy. · Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom. · IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy. · Department of Medical Sciences, University of Torino Medical School, Torino, Italy. · Department of Oncology, University of Torino Medical School, Torino, Italy. · Pubmed 29691252
  • Experimental Therapeutics Group. · High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Oncogenetics Group. · Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge. · AstraZeneca, Gatehouse Park, Waltham, USA. · DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Cancer Genomics Group. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Radiology. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP). · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona. · Ramón y Cajal University Hospital, Madrid. · Vall d'Hebron Institute of Oncology, Barcelona. · Department of Biochemistry and Molecular Biology, Building M, Campus UAB, Bellaterra (Cerdanyola del Vallès). · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona. · CIBERONC, Barcelona. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · DNA Damage Response Biology Area, Oncology Innovative Medicine and Early Development Biotech Unit, AstraZeneca, Cambridge, UK. · Pubmed 29635390
  • CRUK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. · Novocraft Technologies Sdn Bhd, C-23A-05, 3 Two Square, Jalan 19/1, Section 19, 46300, Petaling Jaya, Selangor Darul Ehsan, Malaysia. · CRUK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. · Pubmed 29304755
2016
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, United Kingdom. · Breast Cancer Programme, Cambridge Cancer Centre, Cambridge CB2 2QQ, United Kingdom. · Pubmed 28381438
  • Breast Cancer Functional GenomicsCRUK Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK · Breast Cancer Functional GenomicsCRUK Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of OncologyUniversity of Cambridge, Cambridge, UK · Pubmed 27702751
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. · Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK. · DNA Damage Response Biology Area, Oncology IMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. · OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. · Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain. · Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA. · Translational Research Department, Institut Curie, 26 rue d'Ulm, Paris 75005, France. · Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address: · Pubmed 27641504
2015
  • Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. · Dame Roma Mitchell Cancer Research Laboratories and the Adelaide Prostate Cancer Research Centre, School of Medicine, Hanson Institute Building, University of Adelaide, Adelaide, South Australia 5005, Australia. · Department of Urology, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA. · Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, North Carolina 27599, USA. · 1] Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK [2] Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK [3] Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK. · Pubmed 26153859
  • 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. · Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada. · 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada. · Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [2] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Pubmed 25470049
Probable:    University of London      
2019
  • Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada. · NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK. · Strangeways Research Laboratory, University of Cambridge, Cambridge, UK. · Departamento de Estadística e Investigación Operativa, Universidad de Valladolid, Valladolid, Spain. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Pubmed 30867590
2018
  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada. · Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada. · CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada. · Department of Medical Oncology, University Hospital of Parma, Parma, Italy. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain. · CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. · Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Pathology, Dalhousie University, Halifax, NS, Canada. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · AstraZeneca, Waltham, MA, USA. · Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · XenTech, Evry, France. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Pubmed 30377213
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Regenerative Medicine Center, University Medical Center Utrecht Uppsalalaan 6, Utrecht, The Netherlands. · Mechanisms of Transcription Laboratory, The Francis Crick Institute, London NW1 1AT, UK. · Cancer Research UK Cambridge Institute, and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3484 EA Utrecht, The Netherlands. · Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge CB2 2QQ, UK. · Pubmed 30137431
  • The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Academic Urology Group, Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Institute of Molecular Biology (IMB), Mainz, Germany. · Department of Biochemistry, University of Cambridge, Cambridge, UK. · Wellcome Trust Sanger Institute, Hinxton, UK. · AstraZeneca, Waltham, MA, USA. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · AstraZeneca, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Pubmed 30022119
  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, UK. · Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Pubmed 29795445
  • Department of Oncology, University of Torino Medical School, Torino, Italy. · Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. · Molecular Medicine Program, European Institute of Oncology, Milan, Italy. · Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom. · IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy. · Department of Medical Sciences, University of Torino Medical School, Torino, Italy. · Department of Oncology, University of Torino Medical School, Torino, Italy. · Pubmed 29691252
  • Experimental Therapeutics Group. · High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Oncogenetics Group. · Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge. · AstraZeneca, Gatehouse Park, Waltham, USA. · DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Cancer Genomics Group. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Radiology. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP). · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona. · Ramón y Cajal University Hospital, Madrid. · Vall d'Hebron Institute of Oncology, Barcelona. · Department of Biochemistry and Molecular Biology, Building M, Campus UAB, Bellaterra (Cerdanyola del Vallès). · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona. · CIBERONC, Barcelona. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · DNA Damage Response Biology Area, Oncology Innovative Medicine and Early Development Biotech Unit, AstraZeneca, Cambridge, UK. · Pubmed 29635390
2016
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, United Kingdom. · Breast Cancer Programme, Cambridge Cancer Centre, Cambridge CB2 2QQ, United Kingdom. · Pubmed 28381438
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. · Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK. · DNA Damage Response Biology Area, Oncology IMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. · OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. · Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain. · Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA. · Translational Research Department, Institut Curie, 26 rue d'Ulm, Paris 75005, France. · Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address: · Pubmed 27641504
2015
  • Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. · Dame Roma Mitchell Cancer Research Laboratories and the Adelaide Prostate Cancer Research Centre, School of Medicine, Hanson Institute Building, University of Adelaide, Adelaide, South Australia 5005, Australia. · Department of Urology, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA. · Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, North Carolina 27599, USA. · 1] Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK [2] Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK [3] Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK. · Pubmed 26153859
  • 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. · Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada. · 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada. · Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [2] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Pubmed 25470049
Probable:    Miscellaneous institutions in Cambridge, UK      
2018
  • Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom. · Department of Life Sciences, Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. · Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands. · Pubmed 30507376
2012
  • Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · Pubmed 22968701
2011
  • Cancer Research UK, Cambridge Research Institute, Cambridge, UK. · Pubmed 21337521
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 16 total) written by Alejandra Bruna about Breast Neoplasms:

  • Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. 2019
  • Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. 2018
  • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. 2018
  • SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis. 2018
  • Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. 2018
  • MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. 2018
  • High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis. 2018
  • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. 2018
  • Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. 2018
  • Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts. 2016
Show List of Full Article Records
Google Searches

Learn more about Alejandra Bruna using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
University of Cambridge
University of London
Miscellaneous institutions in Cambridge, UK
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
University of Cambridge
2019
  • Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada. · NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK. · Strangeways Research Laboratory, University of Cambridge, Cambridge, UK. · Departamento de Estadística e Investigación Operativa, Universidad de Valladolid, Valladolid, Spain. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Pubmed 30867590
2018
  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada. · Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada. · CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada. · Department of Medical Oncology, University Hospital of Parma, Parma, Italy. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain. · CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. · Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Pathology, Dalhousie University, Halifax, NS, Canada. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · AstraZeneca, Waltham, MA, USA. · Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · XenTech, Evry, France. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Pubmed 30377213
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Regenerative Medicine Center, University Medical Center Utrecht Uppsalalaan 6, Utrecht, The Netherlands. · Mechanisms of Transcription Laboratory, The Francis Crick Institute, London NW1 1AT, UK. · Cancer Research UK Cambridge Institute, and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3484 EA Utrecht, The Netherlands. · Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge CB2 2QQ, UK. · Pubmed 30137431
  • The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Academic Urology Group, Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Institute of Molecular Biology (IMB), Mainz, Germany. · Department of Biochemistry, University of Cambridge, Cambridge, UK. · Wellcome Trust Sanger Institute, Hinxton, UK. · AstraZeneca, Waltham, MA, USA. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · AstraZeneca, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Pubmed 30022119
  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, UK. · Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Pubmed 29795445
  • Department of Oncology, University of Torino Medical School, Torino, Italy. · Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. · Molecular Medicine Program, European Institute of Oncology, Milan, Italy. · Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom. · IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy. · Department of Medical Sciences, University of Torino Medical School, Torino, Italy. · Department of Oncology, University of Torino Medical School, Torino, Italy. · Pubmed 29691252
  • Experimental Therapeutics Group. · High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Oncogenetics Group. · Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge. · AstraZeneca, Gatehouse Park, Waltham, USA. · DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Cancer Genomics Group. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Radiology. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP). · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona. · Ramón y Cajal University Hospital, Madrid. · Vall d'Hebron Institute of Oncology, Barcelona. · Department of Biochemistry and Molecular Biology, Building M, Campus UAB, Bellaterra (Cerdanyola del Vallès). · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona. · CIBERONC, Barcelona. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · DNA Damage Response Biology Area, Oncology Innovative Medicine and Early Development Biotech Unit, AstraZeneca, Cambridge, UK. · Pubmed 29635390
  • CRUK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. · Novocraft Technologies Sdn Bhd, C-23A-05, 3 Two Square, Jalan 19/1, Section 19, 46300, Petaling Jaya, Selangor Darul Ehsan, Malaysia. · CRUK Cambridge Institute and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. · Pubmed 29304755
2016
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, United Kingdom. · Breast Cancer Programme, Cambridge Cancer Centre, Cambridge CB2 2QQ, United Kingdom. · Pubmed 28381438
  • Breast Cancer Functional GenomicsCRUK Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK · Breast Cancer Functional GenomicsCRUK Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of OncologyUniversity of Cambridge, Cambridge, UK · Pubmed 27702751
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. · Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK. · DNA Damage Response Biology Area, Oncology IMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. · OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. · Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain. · Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA. · Translational Research Department, Institut Curie, 26 rue d'Ulm, Paris 75005, France. · Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address: · Pubmed 27641504
2015
  • Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. · Dame Roma Mitchell Cancer Research Laboratories and the Adelaide Prostate Cancer Research Centre, School of Medicine, Hanson Institute Building, University of Adelaide, Adelaide, South Australia 5005, Australia. · Department of Urology, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA. · Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, North Carolina 27599, USA. · 1] Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK [2] Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK [3] Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK. · Pubmed 26153859
  • 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. · Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada. · 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada. · Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [2] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Pubmed 25470049
University of London
2019
  • Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada. · NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and Research Oncology, Cancer Division, King's College London, London, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. · Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK. · Strangeways Research Laboratory, University of Cambridge, Cambridge, UK. · Departamento de Estadística e Investigación Operativa, Universidad de Valladolid, Valladolid, Spain. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. · Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. · Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. · Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. · Pubmed 30867590
2018
  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada. · Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada. · CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada. · Department of Medical Oncology, University Hospital of Parma, Parma, Italy. · Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain. · CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. · Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · Department of Pathology, Dalhousie University, Halifax, NS, Canada. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · AstraZeneca, Waltham, MA, USA. · Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · XenTech, Evry, France. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain · Pubmed 30377213
  • Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Regenerative Medicine Center, University Medical Center Utrecht Uppsalalaan 6, Utrecht, The Netherlands. · Mechanisms of Transcription Laboratory, The Francis Crick Institute, London NW1 1AT, UK. · Cancer Research UK Cambridge Institute, and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3484 EA Utrecht, The Netherlands. · Cancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge CB2 2QQ, UK. · Pubmed 30137431
  • The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Academic Urology Group, Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Institute of Molecular Biology (IMB), Mainz, Germany. · Department of Biochemistry, University of Cambridge, Cambridge, UK. · Wellcome Trust Sanger Institute, Hinxton, UK. · AstraZeneca, Waltham, MA, USA. · Vall d'Hebron Institute of Oncology, Barcelona, Spain. · AstraZeneca, Cambridge, UK. · Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. · Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK. · Pubmed 30022119
  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, CB2 0RE, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2QQ, UK. · Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. · Pubmed 29795445
  • Department of Oncology, University of Torino Medical School, Torino, Italy. · Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. · Molecular Medicine Program, European Institute of Oncology, Milan, Italy. · Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom. · IFOM, The FIRC Institute for Molecular Oncology Foundation, Milan, Italy. · Department of Medical Sciences, University of Torino Medical School, Torino, Italy. · Department of Oncology, University of Torino Medical School, Torino, Italy. · Pubmed 29691252
  • Experimental Therapeutics Group. · High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Oncogenetics Group. · Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge. · AstraZeneca, Gatehouse Park, Waltham, USA. · DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK. · Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · Cancer Genomics Group. · Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona. · Department of Radiology. · Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona. · Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Human Oncology and Pathogenesis Program (HOPP). · Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. · Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona. · Ramón y Cajal University Hospital, Madrid. · Vall d'Hebron Institute of Oncology, Barcelona. · Department of Biochemistry and Molecular Biology, Building M, Campus UAB, Bellaterra (Cerdanyola del Vallès). · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona. · CIBERONC, Barcelona. · Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. · DNA Damage Response Biology Area, Oncology Innovative Medicine and Early Development Biotech Unit, AstraZeneca, Cambridge, UK. · Pubmed 29635390
2016
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, United Kingdom. · Breast Cancer Programme, Cambridge Cancer Centre, Cambridge CB2 2QQ, United Kingdom. · Pubmed 28381438
  • Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. · Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. · Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK. · DNA Damage Response Biology Area, Oncology IMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. · OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. · Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain. · Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA. · Translational Research Department, Institut Curie, 26 rue d'Ulm, Paris 75005, France. · Huntsman Cancer Institute, Salt Lake City, UT 84112, USA. · Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address: · Pubmed 27641504
2015
  • Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK. · Dame Roma Mitchell Cancer Research Laboratories and the Adelaide Prostate Cancer Research Centre, School of Medicine, Hanson Institute Building, University of Adelaide, Adelaide, South Australia 5005, Australia. · Department of Urology, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA. · Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 450 West Drive, CB7295, Chapel Hill, North Carolina 27599, USA. · 1] Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK [2] Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK [3] Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK. · Pubmed 26153859
  • 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. · Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK [2] Cancer Research UK Cambridge Research Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · 1] Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada [2] Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada. · 1] Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] The Vancouver Prostate Centre, Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V5Z 1M9, Canada. · Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada [2] Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [2] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada. · 1] Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada [3] Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 1L3, Canada [4] Centre for Translational and Applied Genomics, BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada. · Pubmed 25470049
Miscellaneous institutions in Cambridge, UK
2018
  • Department of Cell Biology, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom. · Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom. · Department of Life Sciences, Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom. · Division of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. · Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands. · Pubmed 30507376
2012
  • Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. · Pubmed 22968701
2011
  • Cancer Research UK, Cambridge Research Institute, Cambridge, UK. · Pubmed 21337521
Yearly article counts 18032001100
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.